Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience
Authors:
Open Access
- 6 July 2020
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 18 (1) , 1-11
Abstract
Background: The genomic alterations of intrahepatic cholangiocarcinoma (ICC) in the Chinese population have not been fully revealed. Molecular profiling may provide a reference for clinical management, especially targeted therapy. Methods: A retrospective study was conducted in 122 ICC patients. All patients’ samples underwent next-generation sequencing (NGS), which analyzed 417 genes. The genetic characteristics, clinical management and therapeutic responses were analyzed. Results: The most commonly mutated genes were TP53 (34%), KRAS (25%) and ARID1A (17%). Targeted agents were used referring to molecular profiling, in combination with chemotherapy. Twenty-two patients with wild-type KRAS/NRAS/BRAF were treated with cetuximab. The disease control and response rates were 78% and 47%, respectively, which were higher than those achieved with chemotherapy alone (72% and 11%, P = 0.16). Fifty-four patients underwent anti-VEGF treatment with bevacizumab. The disease control and response rates were 85% and 60%, respectively. Better therapeutic efficiency (P = 0.001) and longer progression-free survival (PFS) were observed in the bevacizumab-treated group compared to chemotherapy alone group (15.4 and 6.7 months, respectively; P = 0.04). The PFS of ten patients who underwent hepatectomy after combined treatment with chemotherapy and bevacizumab was longer than that of 139 patients who underwent surgical treatment (28.9 vs 18.0 months, P = 0.03). Two patients (1.6%) had signatures of microsatellite instability (MSI-H), and both benefited from immunotherapy. Conclusions: This study provides an overview of genetic alterations in Chinese ICC patients and indicates the potential clinical implications for NGS-based personalized therapies.Keywords
All Related Versions
Funding Information
- Wu Jieping Medical Foundation (320.2710.1857)
- National Natural Science Foundation of China (81874182, 81874056)
- National Key Project of China (2017ZX10203204-007-004)
This publication has 39 references indexed in Scilit:
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 studyThe Lancet Oncology, 2020
- Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker programBMC Cancer, 2019
- Biliary carcinomas: pathology and the role of DNA mismatch repair deficiencyChinese Clinical Oncology, 2016
- Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical managementCancer Letters, 2016
- Precision medicine for cancer with next-generation functional diagnosticsNature Reviews Cancer, 2015
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trialThe Lancet Oncology, 2014
- Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancerAnnals of Oncology, 2012
- Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2012
- Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 studyThe Lancet Oncology, 2010